OS Therapies Incorporated (NYSEAMERICAN:OSTX – Get Free Report)’s share price was up 9.4% during trading on Tuesday. The company traded as high as $0.7699 and last traded at $0.7448. 1,162,974 shares traded hands during trading, an increase of 77% from the average daily volume of 656,016 shares. The stock had previously closed at $0.6807.
OS Therapies Trading Up 9.4%
The stock has a market cap of $34.36 million, a P/E ratio of -0.68 and a beta of -0.47. The stock has a 50 day simple moving average of $1.39 and a 200 day simple moving average of $1.53.
Institutional Trading of OS Therapies
Large investors have recently modified their holdings of the stock. Empowered Funds LLC bought a new position in shares of OS Therapies in the third quarter worth $71,000. Sanders Morris Harris LLC acquired a new position in OS Therapies in the third quarter valued at about $32,000. Finally, AXQ Capital LP acquired a new position in OS Therapies in the second quarter valued at about $47,000.
OS Therapies Company Profile
OS Therapies is a clinical-stage biotechnology company focused on developing treatments for osteosarcoma, a rare bone cancer, and potentially other cancers. Its work centers on therapies intended to address the significant risk of recurrence and spread associated with the disease. The company’s lead candidate, OST-HER2, is an investigational immunotherapy designed to stimulate an immune response against HER2-expressing cancer cells. OS Therapies has studied it for osteosarcoma, including disease that has spread to the lungs.
Recommended Stories
- Five stocks we like better than OS Therapies
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for OS Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OS Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
